Company / Gross Profit
Tandem Diabetes Care Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$546.0M
FY2025
5-year range
$194.2M / $546.0M
FY2021-FY2025
Trend
+11.5%
vs FY2024
Sector context
#54 of 100
Health Care
What the data says
At $546M, Tandem Diabetes Care's gross profit ranks #54 of 100 in the Health Care sector. Gross Profit has increased for 7 consecutive years, from $24M in FY2018 to $546M in FY2025.
Based on SEC 10-K filings.
$546M in FY2025 with a 5-year CAGR of +43.5%.
Improved from $368M to $546M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +28.0%
- 5-Year CAGR
- +43.5%
- 10-Year CAGR
- -
Sector benchmark
#54 of 100 in Health CareTop 54% of 100This company $546.0M Sector average $1.8B
▼
-70.0% below sector average
Key checks
Key Insights
- Tandem Diabetes Care's gross profit has grown for 7 consecutive years.
- 5-year CAGR of +43.5%, indicating consistent growth.
- In FY2025, gross profit increased 11.5% year-over-year.
- Ranks #54 out of 100 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $546.0M | +11.5% |
| FY2024 | $489.6M | +33.1% |
| FY2023 | $367.7M | +41.1% |
| FY2022 | $260.5M | +34.1% |
| FY2021 | $194.2M | +116.2% |
| FY2020 | $89.8M | +103.7% |
| FY2019 | $44.1M | +86.9% |
| FY2018 | $23.6M | -11.2% |
| FY2017 | $26.6M | +12.7% |
| FY2016 | $23.6M | -11.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026